Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Department of Psychiatry and Psychology, Maastricht University Medical Centre, Maastricht, the Netherlands; 2King’s College London, King’s Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, UK; 3Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Список исп. литературыСкрыть список 1. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015;30:388-404. 2. Schultze-Lutter F, Michel C, Schmidt SJ et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry 2015;30: 405-16. 3. Kablinger AS, Freeman AM 3rd. Prodromal schizophrenia and atypical antipsychotic treatment. J Nerv Ment Dis 2000;188:642-52. 4. Van Os J, Delespaul P. Toward a world consensus on prevention of schizophrenia. Dialogues Clin Neurosci 2005;7:53-67. 5. Lacluyse K, van Bouwel L, Demunter H et al. Clinical assessment of the ultra high risk of developing a psychotic disorder; review and critical reflection. Tijdschr Psychiatr 2011;53:153-62. 6. Amos A. Assessing the cost of early intervention in psychosis: a systematic review. Aust N Z J Psychiatry 2012;46:719-34. 7. Marshall C, Addington J, Epstein I et al. Treating young individuals at clinical high risk for psychosis. Early Interv Psychiatry 2012;6:60-8. 8. Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatr Scand 2013;127:248-52. 9. Amos AJ. Evidence that treatment prevents transition to psychosis in ultra-high-risk patients remains questionable. Schizophr Res 2014;153: 240. 10. Simon AE, Umbricht D, Lang UE et al. Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome. Schizophr Res 2014;159: 292-8. 11. Mittal VA, Dean DJ, Mittal J et al. Ethical, legal, and clinical considerations when disclosing a high-risk syndrome for psychosis. Bioethics 2015;29: 543-56. 12. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37. 13. Salokangas RK, Heinimaa M, Fr om T et al. Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the EPOS project. Eur Psychiatry 2014;29:371-80. 14. van der Gaag M, Nieman DH, Rietdijk J et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012;38:1180-8. 15. Morrison AP, French P, Stewart SL et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012;344:e2233. 16. Ajnakina O. First episode psychosis: looking backwards and forwards. https://kclpure.kcl.ac.uk. 17. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ (Clin Res Ed) 1981;282:1847-51. 18. Addington J, Case N, Saleem MM et al. Substance use in clinical high risk for psychosis: a review of the literature. Early Interv Psychiatry 2014;8:104-12. 19. Fusar-Poli P, Nelson B, Valmaggia L et al. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 2014;40: 120-31. 20. Fusar-Poli P, Cappucciati M, Borgwardt S et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry 2016;73:113-20. 21. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013;43: 1133-49. 22. van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 2016;15:118-24. 23. Perlis RH, Uher R, Ostacher Met al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011;68:351-60. 24. Kelleher I, Keeley H, Corcoran P et al. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. Br J Psychiatry 2012;201: 26-32. 25. Wigman JT, van Nierop M, Vollebergh WA et al. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity – implications for diagnosis and ultrahigh risk research. Schizophr Bull 2012;38:247-57. 26. Wigman JT, van Os J, Abidi L et al. Subclinical psychotic experiences and bipolar spectrum features in depression: association with outcome of psychotherapy. Psychol Med 2014;44:325-36. 27. Guloksuz S, van Nierop M, Lieb R et al. Evidence that the presence of psychosis in non-psychotic disorder is environment-dependent and mediated by severity of non-psychotic psychopathology. Psychol Med 2015;45: 2389-401. 28. van Nierop M, Viechtbauer W, Gunther N et al. Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries. Psychol Med 2015; 45:1277-88. 29. Woods SW, Addington J, Cadenhead KS et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009;35:894-908. 30. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37. 31. Velthorst E, Nieman DH, Becker HE et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res 2009;109:60-5. 32. Carrion RE, McLaughlin D, Goldberg TE et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013;70:1133-42. 33. Nelson B, Yuen HP, Wood SJ et al. Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry 2013;70:793-802. 34. Falkenberg I, Valmaggia L, Byrnes M et al. Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? Psychiatry Res 2015;228:808- 15. 35. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005;39:964-71. 36. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-5. 37. Simon AE, Velthorst E, Nieman DH et al. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 2011;132:8-17. 38. Lin A, Wood SJ, Nelson B et al. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 2011;132:1-7. 39. Brandizzi M, Valmaggia L, Byrne M et al. Predictors of functional outcome in individuals at high clinical risk for psychosis at six years follow-up. J Psychiatr Res 2015;65:115-23. 40. Simon AE, Roth B, Zmilacher S et al. Developing services for the early detection of psychosis: a critical consideration of the current state of the art. Eur Child Adolesc Psychiatry 2007;16:96-103. 41. Kaymaz N, Drukker M, Lieb R et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking populationbased samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 2012;42:2239-53. 42. Fusar-Poli P, Schultze-Lutter F, Cappucciati M et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull 2016;42:732-43. 43. Conrad AM, Lewin TJ, Sly KA et al. Utility of risk-status for predicting psychosis and related outcomes: evaluation of a 10-year cohort of presenters to a specialised early psychosis community mental health service. Psychiatry Res 2017;247:336-44. 44. Anticevic A, Haut K, Murray JD et al. Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk. JAMA Psychiatry 2015;72:882-91. 45. Cannon TD, Chung Y, He G et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 2015;77:147-57. 46. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M et al. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol 2013;16:471-5. 47. Maxwell SE. The persistence of underpowered studies in psychological research: causes, consequences, and remedies. Psychol Methods 2004;9: 147-63. 48. Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54. 49. McGorry PD, Nelson B, Markulev C et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 2017;74:19-27. 50. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-70. 51. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970;126:983-7. 52. Rietdijk J, Hogerzeil SJ, van Hemert AM et al. Pathways to psychosis: helpseeking behavior in the prodromal phase. Schizophr Res 2011;132:213-9. 53. Woods SW, Addington J, Bearden CE et al. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res 2013;148:99-104. 54. Woodberry KA, Seidman LJ, Bryant C et al. Treatment precedes positive symptoms in North American adolescent and young adult clinical high risk cohort. J Clin Child Adolesc Psychol 2016;5:1-10. 55. Cuijpers P, Donker T, van Straten A et al. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychol Med 2010;40:1943-57. 56. Stain HJ, Bucci S, Baker AL et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr Res 2016;176:212-9. 57. Smith R, Feachem R, Feachem NS et al. The fallacy of impartiality: competing interest bias in academic publications. J R Soc Med 2009; 102:44-5. 58. Open Science Collaboration. An open, large-scale, collaborative effort to estimate the reproducibility of psychological science. Perspect Psychol Sci 2012;7:657-60. 59. van Assen MA, van Aert RC, Nuijten MB et al. Why publishing everything is more effective than selective publishing of statistically significant results. PLoS One 2014;9:e84896. 60. McGorry PD, Tanti C, Stokes R et al. Headspace: Australia’s National Youth Mental Health Foundation – wh ere young minds come first. Med J Aust 2007;187:S68-70. 61. Fusar-Poli P, Yung AR, McGorry P et al. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med 2014;44:17-24.